NIPH Clinical Trials Search

A study on blood component measurements after consumption of the test food

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Healthy Japanese
Date of first enrollment	2026/04/02
Target sample size	9
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	<Duration> Single ingestion <Test food> Test 1: Test food 1 Test 2: Test food 2 *The intervention sequence is Test 1 followed by Test 2. *The washout period is at least one week. <Duration> Single ingestion <Test food> Test 1: Test food 2 Test 2: Test food 1 *The intervention sequence is test 1 followed by test 2. *The washout period is at least one week.

Outcome(s)

Primary Outcome	1. The changes in the concentration of astaxanthin compounds in blood 2. Pharmacokinetic parameters
Secondary Outcome	1. Individuals who experienced adverse events 2. Systolic blood pressure and diastolic blood pressure in Test 1 and Test 2

Key inclusion & exclusion criteria

Age minimum	18years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction 2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator 3. Individuals who are currently receiving treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, chronic kidney disease, cerebrovascular disease, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic disease 4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims 5. Individuals who are taking or using medications (including herbal medicines) or supplements 6. Individuals who are allergic to medications or foods related to the test food 7. Individuals who are pregnant, lactating, or planning pregnancy during this study 8. Individuals who have participated in other clinical studies within 28 days before informed consent, or plan to participate in another study during this study 9. Individuals who have pre-existing gastrointestinal diseases (irritable bowel syndrome, inflammatory bowel disease, gastric ulcer, or gastroesophageal reflux disease) 10. Individuals who are deemed unsuitable for participation in this study by the principal investigator